Parliamentary Search

Written question asked by Chris Green (Conservative) on Friday, 1 September 2023, in the House of Commons. It was due for an answer on Tuesday, 5 September 2023. It was answered by George Freeman (Conservative) on Monday, 11 September 2023 on behalf of the Department for Science, Innovation and Technology.

Voluntary Scheme for Branded Medicines Pricing and Access: Life Sciences

Question

To ask the Secretary of State for Science, Innovation and Technology, whether she has made an assessment of potential links between the Voluntary Scheme for Branded Medicines Pricing and Access and levels of foreign direct investment in life sciences.

Answer

The Government has considered in broad terms the link between volume-based rebate payments in our medicine pricing schemes and various kinds of investment in our Impact Assessment of updates to the Statutory Scheme for branded medicines pricing, which operates alongside voluntary scheme for branded medicines pricing and access (VPAS). The Government’s 2023 Impact Assessment of updates to the Statutory Scheme can be found here: www.gov.uk/government/consultations/review-of-the-scheme-to-control-the-cost-of-branded-health-service-medicines.

We are in close discussions with the Department of Health and Social Care and Department for Business and Trade about the business environment for life sciences and its impact on investment.

Secondary information

Type
Written question
Reference
195969
Session
2022-23
Transferred
Yes
Subjects
Foreign investment in UK Life sciences Voluntary scheme for branded medicines pricing and access
Link
View this Written question on www.parliament.uk